VANCOUVER, British Columbia--(BUSINESS WIRE)--July 6, 2006--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has cited a growing body of both basic scientific evidence -- as well as real-world treatment practices at leading cardiac care institutions -- that further validate the Company’s core technology and business strategy to make a safer generation of coronary stents based on its proprietary bio-friendly stent coatings.
